「cui」の検索結果

Fornece orientação para pesquisa de interpretabilidade mecanística usando TransformerLens para inspecionar e manipular internals de transformers via HookPoints e caching de ativações. Use ao fazer engenharia reversa de algoritmos de modelos, estudar padrões de atenção ou realizar experimentos de activation patching.

日本語の概要は準備中です。原文の説明を表示しています。

Knowledge base from the DoD Test & Evaluation Enterprise Guidebook (OUSD R&E, August 2022). Use for DoD test and evaluation (T&E) across the Adaptive Acquisition Framework — the four test communities (contractor testing, developmental DT&E, operational OT&E, live-fire LFT&E); the five operational events (Operational Demonstration, EOA, OA, IOT&E, FOT&E) and the OTRR gate; the T&E Strategy / TEMP and its IDSK, with the upstream documents that feed it and the test plans that decompose it; the T&E organizations and oversight roles (USD(R&E), DOT&E, TRMC, the Service Executives and OTAs, the T&E WIPT, CDT); and pathway-specific T&E for all six acquisition pathways (Urgent Capability, Middle Tier, Major Capability, Software, Defense Business Systems). Statutory anchors include 10 U.S.C. §4171 (IOT&E) and §4172 (LFT&E/FUSL). This is guidance, not policy: it points outward to DoDI 5000.89 and the DoDI 5000-series for binding detail, and is thin on detailed test statistics/design-of-experiments methodology, cost estimating, the Acquisition of Services pathway, and any CUI/CAC-gated companion guides.

日本語の概要は準備中です。原文の説明を表示しています。

Knowledge base from the FAA System Safety Handbook (Dec 30, 2000). Use for system safety as a specialty within systems engineering: the five-step safety risk management process (mandated by FAA Order 8040.4 and the AMS), the severity-by-likelihood risk matrix and acceptance bands, the Safety Order of Precedence, system-description models (5M, SHEL(L)), the hazard-analysis activities (PHL/PHA/RHA/SSHA/SHA/O&SHA/HHA), integrated system hazard analysis, the analysis techniques (FTA, FMEA/FMECA, Fault Hazard, Common Cause, Sneak Circuit, Energy Trace), closed-loop hazard tracking (Safety Action Record), and the specialty domains the handbook covers — acquisition-lifecycle safety and contracting (OSA/CSA/SSPP/ISSPP), software safety (control-capability ranking, SHCM, DO-178B), test & evaluation safety, facilities safety, commercial launch safety (AST licensing, expected casualty, MPL/DAMP), system safety training, and Operational Risk Management (ORM) with human/organizational factors. Scope limits: this is a year-2000 FAA how-to; it predates the modern FAA/ICAO Safety Management System (SMS) and Just Culture regulatory frameworks, and many cited orders, advisory circulars, and launch-licensing rules have since been restructured. It is FAA/NAS-centric, leans on MIL-STD-882C, and does not define the SE life-cycle processes themselves (use nasa-npr-7123 / dau-se-guidebook) or reproduce third-party standard text (MIL-STD-882, DO-178B, ISO/IEC/IEEE).

日本語の概要は準備中です。原文の説明を表示しています。

Psicoeducación sobre el trauma: definición de trauma, reacciones normales, ventana de tolerancia, manejo de desencadenantes y autocuidado.

日本語の概要は準備中です。原文の説明を表示しています。

Writes, runs and reviews mobile tests across Flutter, native Android, native iOS, React Native and Kotlin Multiplatform. Covers Dart widget/integration tests, JUnit/Compose/Espresso, XCTest/XCUITest, Jest/Detox, and KMP common/target tests. Use to add, fix, run or audit tests, test setup, mocks, coverage and flaky tests for a real app behavior.

日本語の概要は準備中です。原文の説明を表示しています。

Write and migrate tests using the Swift Testing framework with @Test, @Suite, #expect, #require, confirmation, parameterized tests, test tags, traits, withKnownIssue, XCTest UI testing, XCUITest, test plan, mocking, test doubles, testable architecture, snapshot testing, async test patterns, test organization, and test-driven development in Swift. Use when writing or migrating tests with Swift Testing framework, implementing parameterized tests, working with test traits, converting XCTest to Swift Testing, or setting up test organization and mocking patterns.

日本語の概要は準備中です。原文の説明を表示しています。

レッドストーン回路の自動テストが失敗した際の切り分け・局所修正手順。get_blocks, interact_block, place_blocks を使ったデバッグ方法を定義する。

クロック回路の論理、構成方法（リピーター、ホッパー、オブザーバー等）、および使用に関するガイドラインです。

レッドストーン回路の自動テストが失敗した際の切り分け・局所修正手順。CLI版の mc-cli get-blocks, interact-block, place-blocks を使ったデバッグ方法を定義する。

Multi-agent autonomous startup system for Claude Code. Triggers on "Loki Mode". Orchestrates 100+ specialized agents across engineering, QA, DevOps, security, data/ML, business operations, marketing, HR, and customer success. Takes PRD to fully deployed, revenue-generating product with zero human intervention. Features Task tool for subagent dispatch, parallel code review with 3 specialized reviewers, severity-based issue triage, distributed task queue with dead letter handling, automatic deployment to cloud providers, A/B testing, customer feedback loops, incident response, circuit breakers, and self-healing. Handles rate limits via distributed state checkpoints and auto-resume with exponential backoff. Requires --dangerously-skip-permissions flag.

日本語の概要は準備中です。原文の説明を表示しています。

Siber Vatan CTF playbook — flag formats, web/reverse/forensics/blockchain/OSINT/stego/crypto recipes, and pivot heuristics tailored to the Turkish CTF circuit.

日本語の概要は準備中です。原文の説明を表示しています。

Quantum physics simulation library for open quantum systems. Use when studying master equations, Lindblad dynamics, decoherence, quantum optics, or cavity QED. Best for physics research, open system dynamics, and educational simulations. NOT for circuit-based quantum computing—use qiskit, cirq, or pennylane for quantum algorithms and hardware execution.

日本語の概要は準備中です。原文の説明を表示しています。

Designs adaptive clinical trials including group-sequential (O'Brien-Fleming, Pocock, Lan-DeMets spending), sample-size re-estimation (blinded Friede-Kieser, unblinded Cui-Hung-Wang, Mehta-Pocock promising zone), seamless Phase 2/3 with treatment-arm selection, population enrichment, and response-adaptive randomisation. Covers FDA 2019 Final Adaptive Designs Guidance, FDA 2022 Master Protocols, and ICH E20 Step 2b/3 draft (June 2025, NOT final). Use when planning interim analyses, sample-size re-estimation, or master/platform-trial designs.

日本語の概要は準備中です。原文の説明を表示しています。

Hardware-agnostic quantum ML framework with automatic differentiation. Use when training quantum circuits via gradients, building hybrid quantum-classical models, or needing device portability across IBM/Google/Rigetti/IonQ. Best for variational algorithms (VQE, QAOA), quantum neural networks, and integration with PyTorch/JAX/TensorFlow. For hardware-specific optimizations use qiskit (IBM) or cirq (Google); for open quantum systems use qutip.

日本語の概要は準備中です。原文の説明を表示しています。

Provides guidance for mechanistic interpretability research using TransformerLens to inspect and manipulate transformer internals via HookPoints and activation caching. Use when reverse-engineering model algorithms, studying attention patterns, or performing activation patching experiments.

日本語の概要は準備中です。原文の説明を表示しています。

Calls m6A peaks from MeRIP-seq / m6A-seq paired IP-vs-input data using exomePeak2 (transcript-aware, GC-bias-corrected Poisson GLM; Liu 2022 *NAR Genom Bioinform* 4:lqac046), MeTPeak (HMM over sliding windows; Cui 2016 *Bioinformatics* 32:i378), MACS3 / MACS2 with --nomodel --broad --keep-dup all (genome-wide broad alternative), and DRACH motif enrichment confirmation via HOMER or ggseqlogo as a sanity check (NOT a filter). Covers BED12 vs narrowPeak output formats, exonic vs intronic peak handling, multi-tool reconciliation (intersection vs union; cross-caller IDR-equivalent), the m6A-vs-m6Am ambiguity at 5'UTR peaks that antibody-based methods cannot resolve, and orthogonal-validation routes (miCLIP / GLORI / m6A-SAC-seq / m6Anet). Use when calling peaks from paired IP/input genome BAMs, choosing exomePeak2 (transcript-aware default) vs MACS3 (broad genomic) vs MeTPeak (HMM-smoothed low-coverage), confirming DRACH enrichment as a sanity check on the peak set as a whole, reconciling differing peak sets across tools, validating MeRIP peaks against orthogonal single-base methods, interpreting peaks at the 5' end where m6Am contamination is possible, or recommending a multi-tool consensus strategy.

日本語の概要は準備中です。原文の説明を表示しています。

Tests genotype-environment associations and identifies adaptive loci while correcting for the four-confound landscape (structure, demography, background selection, sampling design) using LFMM2 with mandatory K via sNMF cross-entropy elbow (LEA 3), BayPass Core/AUX/C2/IS with Omega covariance matrix, RDA / pRDA for polygenic adaptation (Forester 2018; requires imputed genotypes), OutFLANK with trimmed FST null, pcadapt, gradient forests (Ellis-Smith-Pitcher 2012, NOT mis-cited Ellis-Manel), Capblancq & Forester 2021 RDA Swiss-army-knife, genomic-offset prediction with Lind & Lotterhos 2025 three-regime caveat, Lotterhos-Whitlock sampling optima, Wang & Bradburd 2014 IBD vs IBE, and Circuitscape + ResistanceGA. Use when identifying adaptive loci across gradients, choosing K for LFMM2, deciding among GEA methods, predicting maladaptation with the novel-environment caveat, distinguishing IBD vs IBE, or optimizing sampling design.

日本語の概要は準備中です。原文の説明を表示しています。

Designs adaptive clinical trials including group-sequential (O'Brien-Fleming, Pocock, Lan-DeMets spending), sample-size re-estimation (blinded Friede-Kieser, unblinded Cui-Hung-Wang, Mehta-Pocock promising zone), seamless Phase 2/3 with treatment-arm selection, population enrichment, and response-adaptive randomisation. Covers FDA 2019 Final Adaptive Designs Guidance, FDA 2022 Master Protocols, and ICH E20 Step 2b/3 draft (June 2025, NOT final). Use when planning interim analyses, sample-size re-estimation, or master/platform-trial designs.

日本語の概要は準備中です。原文の説明を表示しています。

Identifies super-enhancers from H3K27ac, MED1, or BRD4 ChIP-seq using ROSE, ROSE2, LILY, HOMER -style super, and ENCODE dELS cross-referencing. Handles peak stitching parameters, ranking choices, hockey-stick inflection, marker choice (H3K27ac vs MED1/BRD4), and cross-condition comparison with spike-in normalization. Constructs core regulatory circuitry (Saint-Andre 2016) from SE-encoded TFs. Use when identifying cell-identity / cancer-associated regulatory domains, comparing super-enhancers between conditions, identifying master transcription factor networks, or predicting BET-inhibitor responsiveness.

日本語の概要は準備中です。原文の説明を表示しています。

Otimiza a estrutura e a conversão de páginas de marketing — hierarquia, ordem das seções, posicionamento de CTA, sinais de confiança e pontos de atrito. Use quando o usuário disser "CRO", "essa página não converte", "melhorar conversão", "por que ninguém clica", "otimizar a landing". Cuida de estrutura; para reescrever o texto ver copy-page.

日本語の概要は準備中です。原文の説明を表示しています。

Tests genotype-environment associations and identifies adaptive loci while correcting for the four-confound landscape (structure, demography, background selection, sampling design) using LFMM2 with mandatory K via sNMF cross-entropy elbow (LEA 3), BayPass Core/AUX/C2/IS with Omega covariance matrix, RDA / pRDA for polygenic adaptation (Forester 2018; requires imputed genotypes), OutFLANK with trimmed FST null, pcadapt, gradient forests (Ellis-Smith-Pitcher 2012, NOT mis-cited Ellis-Manel), Capblancq & Forester 2021 RDA Swiss-army-knife, genomic-offset prediction with Lind & Lotterhos 2025 three-regime caveat, Lotterhos-Whitlock sampling optima, Wang & Bradburd 2014 IBD vs IBE, and Circuitscape + ResistanceGA. Use when identifying adaptive loci across gradients, choosing K for LFMM2, deciding among GEA methods, predicting maladaptation with the novel-environment caveat, distinguishing IBD vs IBE, or optimizing sampling design.

日本語の概要は準備中です。原文の説明を表示しています。

Calls m6A peaks from MeRIP-seq / m6A-seq paired IP-vs-input data using exomePeak2 (transcript-aware, GC-bias-corrected Poisson GLM; Liu 2022 *NAR Genom Bioinform* 4:lqac046), MeTPeak (HMM over sliding windows; Cui 2016 *Bioinformatics* 32:i378), MACS3 / MACS2 with --nomodel --broad --keep-dup all (genome-wide broad alternative), and DRACH motif enrichment confirmation via HOMER or ggseqlogo as a sanity check (NOT a filter). Covers BED12 vs narrowPeak output formats, exonic vs intronic peak handling, multi-tool reconciliation (intersection vs union; cross-caller IDR-equivalent), the m6A-vs-m6Am ambiguity at 5'UTR peaks that antibody-based methods cannot resolve, and orthogonal-validation routes (miCLIP / GLORI / m6A-SAC-seq / m6Anet). Use when calling peaks from paired IP/input genome BAMs, choosing exomePeak2 (transcript-aware default) vs MACS3 (broad genomic) vs MeTPeak (HMM-smoothed low-coverage), confirming DRACH enrichment as a sanity check on the peak set as a whole, reconciling differing peak sets across tools, validating MeRIP peaks against orthogonal single-base methods, interpreting peaks at the 5' end where m6Am contamination is possible, or recommending a multi-tool consensus strategy.

日本語の概要は準備中です。原文の説明を表示しています。

Identifies super-enhancers from H3K27ac, MED1, or BRD4 ChIP-seq using ROSE, ROSE2, LILY, HOMER -style super, and ENCODE dELS cross-referencing. Handles peak stitching parameters, ranking choices, hockey-stick inflection, marker choice (H3K27ac vs MED1/BRD4), and cross-condition comparison with spike-in normalization. Constructs core regulatory circuitry (Saint-Andre 2016) from SE-encoded TFs. Use when identifying cell-identity / cancer-associated regulatory domains, comparing super-enhancers between conditions, identifying master transcription factor networks, or predicting BET-inhibitor responsiveness.

日本語の概要は準備中です。原文の説明を表示しています。

Designs adaptive clinical trials including group-sequential (O'Brien-Fleming, Pocock, Lan-DeMets spending), sample-size re-estimation (blinded Friede-Kieser, unblinded Cui-Hung-Wang, Mehta-Pocock promising zone), seamless Phase 2/3 with treatment-arm selection, population enrichment, and response-adaptive randomisation. Covers FDA 2019 Final Adaptive Designs Guidance, FDA 2022 Master Protocols, and ICH E20 Step 2b/3 draft (June 2025, NOT final). Use when planning interim analyses, sample-size re-estimation, or master/platform-trial designs.

日本語の概要は準備中です。原文の説明を表示しています。